RGNX
REGENXBIO Inc.
$12.27
-0.02 (-0.16%)
At close · Jul 15
Market Cap
$626.32M
Shares
51,697,621
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.27
Open$12.18
Day$11.83–12.36
52W$5.46–16.19
Avg vol 30d2.4M
Short int10.5M · 20.2% float · 3.2d
Short vol22%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 11, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
+35%
above
RSI (14)
57
neutral
MACD trend
Negative
52-week position
63%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+80%
trailing
6-month return
−18%
trailing
YTD return
−15%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $11 — 200d above 50d
Institutional flow
Distributing
8 of 179 funds reported for Jun 30 · net -991.6K sh shares
Insider flow
Distributing
Net -$857.5K over 90 days · 100% sells
Short interest
Rising
20.23% of float · ▲ +12.9% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
179 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+678%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-126.4M
Balance sheet
$34.5M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
+35%
Bullish
RSI (14)
57
Neutral
MACD trend
Negative
Bearish
52-week position
63%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $11 — 200d above 50d
Institutional flow
Distributing
8 of 179 funds reported for Jun 30 · net -991.6K sh shares
Insider flow
Distributing
Net -$857.5K over 90 days · 100% sells
Short interest
Rising
20.23% of float · ▲ +12.9% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
179 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $5
Now $12 · 63%
52-wk high $16
vs 200-day avg +16%
vs 50-day avg +35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGNX
this stock
REGENXBIO Inc.
|
$626.32M | -14.8% | +24.0% | — | 20.2% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGNX | -19.4% | +79.5% | -18.3% | +2.4% | -14.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -20.7% | +79.7% | -28.4% | +1.3% | -25.5% |